Roche launches new diagnostic test for the better understanding of immune response to SARS-CoV-2

Elecsys IGRA SARS-CoV-2 testsupports the better understanding of immuneresponse to SARS-CoV-2 infection or vaccinationThe test detects T-cell response, which may play an important role in determining if immune protection has been achievedThenew diagnostic testmayprovide clinical care guidance, particularly forimmunocompromised and high-risk patient groupsBasel, 15 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys ® IGRA SARS-CoV-2 test in countries that accept the CE Mark1. The Elecsys IGRA SARS-CoV-2 test supports the better understanding of immune response to SARS-CoV-2 infection and vaccination. The test will be an additional tool to make better-informed decisions around care, sanitary measures and treatment options. This will be particularly important for at-risk patient groups.With the transition from a pandemic to an endemic state of COVID-19, there is an increasing need to better understand the adaptive response of the human immune system to SARS-CoV-2. An effective antiviral immune response requires coordinated T- and B-cell activities. While B-cells produce antibodies that can potentially neutralise viruses, T-cells can target infected cells to prevent further viral replication and spread. SARS-CoV-2 infection, as well as COVID-19 vaccination, induce both T- and B-cell responses, in people with a normally functioning immune system, and a timely and well-coordinated T- and B-cell response is likely the key in infection control...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news